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ABSTRACT
We previously reported the tumor suppressor function of Zinc-fingers and 
homeoboxes 2 (ZHX2) in hepatocellular carcinoma (HCC). Other studies indicate 
the association of increased ZHX2 expression with improved response to high dose 
chemotherapy in multiple myeloma. Here, we aim to test whether increased ZHX2 
levels in HCC cells repress multidrug resistance 1(MDR1) expression resulting in 
increased sensitivity to chemotherapeutic drugs. We showed evidence that increased 
ZHX2 levels correlated with reduced MDR1 expression and enhanced the cytotoxicity 
of CDDP and ADM in different HCC cell lines. Consistently, elevated ZHX2 significantly 
reduced ADM efflux in HepG2 cells and greatly increased the CDDP-mediated 
suppression of liver tumor growth in vivo. Furthermore, immunohistochemical staining 
demonstrated the inverse correlation of ZHX2 and MDR1 expression in HCC tissues. 
Luciferase report assay showed that ZHX2 repressed the MDR1 promoter activity, 
while knockdown of NF-YA or mutating the NF-Y binding site eliminated this ZHX2-
mediated repression of MDR1 transcription. Co-IP and ChIP assay further suggested 
that ZHX2 interacted with NF-YA and reduced NF-Y binding to the MDR1 promoter. 
Taken together, we clarify that ZHX2 represses NF-Y-mediated activation of MDR1 
transcription and, in doing so, enhances the effects of chemotherapeutics in HCC cells 
both in vitro and in vivo.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common cancers worldwide with high mortality, and poor 
prognosis. Although a large number of therapeutic agents 
have been evaluated for the treatment of HCC, most 
have been ineffective due to the high chemoresistance, 
especially the multidrug resistance (MDR) of liver cancer 
cells [1, 2]. Overexpression of multidrug resistance 
protein 1(MDR1, also known as p-glycoprotein), an ATP-
dependent pump, causes the efflux of various hydrophobic 
compounds and xenobiotics leading to MDR [3]. 
Accumulated data confirm the important role of MDR1 in 
the resistance of HCC cells against different chemodrugs, 
including the commonly used chemotherapeutic drugs 
cisplatin [cis-diamminedichloroplatinum (CDDP)] 
and Adriamycin (ADM)[4-6] . Strategies targeting 
MDR1 have been recognized as a potential method to 
restore chemotherapeutic sensitivity of cancer cells, 
however, strategies have had minimal clinical benefit 
[3, 7]. Therefore, understanding the regulation of MDR1 
expression in HCC is essential to develop more effective 
treatments. 
Previous studies have identified a number of 
transcription factors binding sites in MDR1 promoter. 
A conserved CCAAT element (Y-box), located between 
-82 to -73 in the human MDR1 promoter is absolutely 
required for basal and inducible expression of the human 
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MDR1 gene [8, 9].The nuclear protein NF-Y, a complex 
consisting of A, B, and C subunits, recognizes the Y-box 
sequences and orchestrates MDR1 promoter activation [9, 
10]. The identification of NF-Y as a central mediator of 
MDR1 activation makes it an attractive molecular target 
for manipulating the MDR phenotype and therapeutic 
intervention. 
 The Zinc-Fingers and Homeoboxes 2 (ZHX2) gene 
is a member of a small gene family that also includes 
ZHX1 and ZHX3 [11]. Two-hybrid studies indicate that 
ZHX2 can form homodimers as well as heterodimers 
with other ZHX family members and with NF-YA [12]. 
Consistent with these data, ZHX2 regulates the NF-YA-
dependent genes cdc25C and Hexokinase II (HKII) and has 
been implicated in cell cycle control [12, 13]. A potential 
role for ZHX2 in HCC came from studies showing 
that ZHX2 represses expression of alpha-fetoprotein 
(AFP), glypican-3 (GPC3) and H19, three genes that 
are frequently activated in HCC [14, 15]. We recently 
demonstrated that ZHX2 overexpression leads to G1 arrest 
and down-regulation of cyclin A and cyclin E expression 
in HCC cell lines [16]. Altered ZHX2 expression has been 
reported in hepatic and hematological malignancies [17-
19]. Interestingly, high ZHX2 expression is significantly 
associated with an improved response and longer survival 
after high dose-chemotherapy in patients with multiple 
myeloma [17], suggesting that ZHX2 might influence drug 
resistance in cancer cells. 
Based on the function of ZHX2 as a transcriptional 
repressor and its known interaction with NF-YA, we 
hypothesized that ZHX2 might inhibit MDR1 expression 
in liver cancer cells, resulting in reduced efflux of 
chemotherapeutic drugs and subsequent increased 
sensitivity to these agents. To test this, the correlation 
of ZHX2 and MDR1 expression was evaluated in HCC 
tissues. Then ZHX2 levels were experimentally increased 
or decreased in several liver cancer cell lines, followed 
by treatment with CDDP and ADM. Our results indicate 
that higher ZHX2 levels reduced MDR1 expression 
and decreased drugs efflux in all HCC lines tested. 
Consistently, ZHX2 significantly enhanced the sensitivity 
of HCC cells to chemotherapeutic drugs both in vitro 
and in vivo. Taken together, our data identify MDR1 as 
a new target of the tumor suppressor ZHX2 and suggest 
that ZHX2 maybe a novel target for the treatment of liver 
cancer. 
RESULTS
The expression level of ZHX2 in HCC tissues 
negatively correlates with that of MDR1 
We first evaluated the correlation of ZHX2 and 
MDR1 expression in HCC tissues. To address that, thirty 
HCC samples were involved to do immunohistochemical 
staining with antibodies against ZHX2 and MDR1. 
Consistent with our previous study [16], nucleic ZHX2 
could be detected in less than 35% (9/30) involved HCC 
cases (Table 1). Moreover, MDR1 expression in HCC 
tissue sections with nucleic ZHX2 was comparatively 
lower than that in HCC tissue sections without nucleic 
ZHX2 (Figure 1). Analysis results of Chi-square test 
and non-parametric test further confirmed the reverse 
correlation of nucleic ZHX2 with MDR1 in HCC (Table 
1). Both the positive percentage (score of 4–12) and 
the expression intensity of nuclear ZHX2 (displayed as 
median ± SD) were significantly lower in MDR1-positive 
staining samples (score of 4–12) than that in MDR1-
negative staining samples (p < 0.05). These indicated 
that reduced nuclear ZHX2 level might be responsible for 
enhanced MDR1 expression in HCC.
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ZHX2 decreases MDR1 expression and reduces 
drug efflux from HCC cells
In order to further confirm the negative regulation 
of ZHX2 on MDR1 in HCC, we then did in vitro studies. 
ZHX2 and MDR1 mRNA levels were compared in several 
liver cancer cell lines. RT-PCR analysis showed an inverse 
correlation between MDR1 and ZHX2 expression: cells 
with higher MDR1 mRNA levels (HepG2 and HepG2.2.15 
cells) had lower ZHX2 mRNA levels whereas those with 
lower MDR1 (SMMC7721 cells) had higher ZHX2 (Figure 
S1A). Interestingly, ZHX2 expression level correlated with 
CDDP sensitivity in HCC cells (Figure S1B), indicating 
that ZHX2 closely correlates with MDR1 expression and 
chemotherapy sensitivity of HCC cells. To explore further 
the relationship between these two genes, ZHX2 was 
overexpressed or knocked down by transient transfection. 
As shown in Figure 2A, ZHX2 overexpression led to 
decreased MDR1 mRNA levels in HepG2 and HepG2.2.15 
cells, whereas ZHX2 knockdown with two different 
siRNAs (ZHX2-1674, ZHX2-2360) resulted in elevated 
MDR1 mRNA levels in SMMC7721 cells. This difference 
was also seen at the protein level as determined by western 
blot (Figure 2B and Figure S2). These data support the 
possibility that ZHX2 represses MDR1 expression in HCC 
cells. 
MDR1 is a well-known ATP-dependent drug efflux 
pump. To evaluate the effect of ZHX2 on regulating the 
MDR1 transporter activity, HepG2 cells were transfected 
with pEGFP-ZHX2 and then treated with ADM, which 
emits a natural red fluorescence. EGFP-ZHX2 expression 
and ADM autofluorescence intensity were detected by 
fluorescence microscopy. As shown in Figure 2C, red 
fluorescence was higher in EGFP-ZHX2 expressing cells 
than untransfected cells after ADM treatment, indicating 
greater ADM accumulation in EGFP-ZHX2 transfected 
cells. Enhanced ADM accumulation in EGFP-ZHX2 
expressing cells was further confirmed by flow cytometry. 
The red MFI in EGFP-positive cells was significantly 
higher than that in EGFP-negative cells 4 hours after 
ADM treatment (Figure 2D, left panel). The red MFI in 
EGFP-positive cells remained higher than EGFP-negative 
cells 2 hours after ADM withdraw (Figure 2D, right 
panel), suggesting enhanced ADM retention in EGFP-
ZHX2 overexpressing cells. Consistently, EGFP-ZHX2 
positive cells exhibited a decreased ADM releasing index 
compared with EGFP-ZHX2 negative cells (Figure 2E). 
Taken together, these data suggest that ZHX2 suppresses 
MDR1 expression and decreases drug efflux, resulting in 
increased intracellular ADM levels. 
Figure 1: ZHX2 expression is inverse correlated to the expression of MDR1 in HCC. Immunohistochemical staining of 
ZHX2 and MDR1 in adjacent sections of cancer biopsies from 2 of the 30 HCC samples (upper panels, ZHX2 high and MDR1 low ; lower 
panels, ZHX2 low and MDR1 high). bars = 50μm; statistical results were shown in Table 1.
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Figure 2: ZHX2 suppresses MDR1 expression and increases ADM retention of HCC cells. (A and B) ZHX2, MDR1 and 
β-actin mRNA levels(A) and protein levels (B) were determined by RT-PCR and western blot in HepG2 and HepG2.2.15 cells transfected 
with pcDNA3.0 or pcZHX2 and in SMMC7721 cells that were transfected with ZHX2 siRNAs or control siRNA (siCON). (C) ZHX2-
EGFP expression and intracellular ADM were determined by fluorescence microscopy of HepG2 cells in pEGFP-ZHX2-transfected cells 
treated with ADM as described in Methods and Materials. Representative panels are shown. Red, autofluorescence of ADM ; Green, 
fluorescence of EGFP-ZHX2 ; Blue, DAPI staining. Bars, 10 μm. (D) ADM accumulation (left panels) and retention (right panels) in 
pEGFP-ZHX2 transfected HepG2 cells were analyzed by flow cytometry. (E) Left panel: ADM accumulation and retention based on data 
in Figure 2D. Right panel: ADM-releasing index was calculated based on accumulation and retention data from flow cytometry. Data are 
shown as the mean±SD (n=3); *p < 0.05.
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Figure 3: Higher ZHX2 levels increase the sensitivity of HCC cells to the cytotoxic effects of CDDP and ADM. HepG2 
and HepG2.2.15 cells were transfected with pcDNA3.0 or pcZHX2 (A), whereas SMMC7721 cells were transfected with siCON or ZHX2-
siRNAs (B). After 24 hours, cells were treated with CDDP (upper panels) or ADM (lower panels) and cultured for another 24 hours. The 
cytotoxicity was calculated as described in Materials and Methods.  Data are shown as the mean±SD (n=4); **p < 0.01, ***p < 0.001. (C 
and D) IC50 of CDDP (upper panels) or ADM (lower panels) in cell lines transfected as described above in A and B. The IC50 was calculated 
as described in Materials and Methods. Data are shown as the mean±SD (n=3); *p < 0.05, **p < 0.01.
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Higher ZHX2 expression increases the cytotoxicity 
of chemotherapeutic drugs
The ability of ZHX2 to repress MDR1 led us to 
consider whether elevated ZHX2 levels would increase 
drug sensitivity in HCC cells. To test this, the cytotoxicity 
index of CDDP or ADM was determined in ZHX2-
overexpressing cells or ZHX2-knockdown cells. In ZHX2-
overexpressing cell lines (HepG2 and HepG2.2.15), the 
cytotoxicity index increased significantly after treatment 
with both CDDP and ADM (Figure 3A) compared to 
pcDNA3.0-transfected cells treated with these drugs. In 
accordance, knock-down of ZHX2 in SMMC7721 cells 
decreased the cytotoxicity index of both CDDP and 
ADM (Figure 3B). This is further supported by IC50 assay 
measured with increasing amounts of CDDP or ADM in 
different cell populations (Figure 3C and D). These data 
indicate that increased ZHX2 levels result in increased 
sensitivity of HCC cells to these chemotherapeutic drugs.
ZHX2 increases CDDP-induced apoptosis in 
HepG2 cells
Since CDDP acts to increase apoptosis by DNA 
cross-linking, we next tested whether elevated ZHX2 
would enhance CDDP-mediated DNA damage and 
apoptosis in HepG2 cells as judged by chromatin 
condensation and nuclear fragmentation [20]. ZHX2 
overexpression by itself did not increase the number 
of apoptotic, sub-G1 cells compared to pcDNA3.0 
transfected cells (Figure 4A). As expected, a distinct 
sub-G1 peak was detected in CDDP-treated HepG2 cells. 
Interestingly, ZHX2 overexpression significantly increased 
the sub-G1 population after CDDP treatment, indicating 
that elevated ZHX2 enhances CDDP-induced apoptosis. 
This increased apoptosis was further verified by Hoechst 
33258 and DAPI staining in HepG2 cells, which showed 
increased chromatin condensation (Figure 4B) and flow 
cytometry after staining with Annexin V and propidium 
iodide (PI, Figure 4C). 
To further analyze the effect of ZHX2 on CDDP-
induced apoptosis, several apoptosis-related proteins 
were monitored by western blot. Consistent with earlier 
studies , CDDP treatment increased levels of cytoplasmic 
Cytochrome C, cleaved caspase-3, cleaved caspase-9 
and cleaved PARP (Figure 4D). Moreover, although 
ZHX2 overexpression did not alter overall levels of these 
proteins, pcZHX2 transfection enhanced the CDDP-
induced levels of apoptotic products (Figure 4D). This 
was particularly true for caspase-9, since nearly twice 
the levels of cleaved caspase-9 were detected in HepG2 
cells transfected with ZHX2 and treated with CDDP 
compared with cells treated with CDDP alone (Figure 
4D, right panel). Collectively, these results indicate that 
ZHX2 overexpression enhanced CDDP cytotoxicity by 
increasing drug-induced apoptosis in HepG2 cells. 
ZHX2 overexpression enhances CDDP-mediated 
inhibition of HCC growth in nude mice 
In order to detect whether ZHX2 and CDDP could 
cooperate to inhibit tumor growth in vivo, HepG2.2.15 
xenograft tumors were treated with CDDP and/or plasmid 
DNA (pcDNA3.0 or pcZHX2). As seen in previous studies 
[16], either CDDP treatment or ZHX2 overexpression 
alone inhibited xenograft growth significantly (Figure 
5A). However, the combination of pcZHX2 and CDDP 
cooperatively inhibited tumor growth to a greater extent 
than treatment with pcZHX2 or CDDP alone (Figure 
5A). Consistent with the diminished growth curves, 
tumor weights at time of sacrifice were also significantly 
reduced in mice with combined treatment compared 
to mice treated with pcZHX2 or CDDP alone (Figure 
5B). Immunohistochemistry staining verified the ZHX2 
overexpression in tumors injected with pcZHX2 (Figure 
5C). TUNEL staining confirmed that ZHX2 promoted 
CDDP-induced apoptosis of tumor cells (Figure 5D). 
These results indicated that ZHX2 overexpression 
enhances the ability of CDDP to inhibit HepG2.2.15 
growth in vivo.
ZHX2-mediated repression on MDR1 promoter 
activity requires NF-Y
Previous studies indicate that ZHX2 functions 
as a transcriptional repressor [9, 12, 13]. We therefore 
tested whether ZHX2 represses MDR1 promoter activity. 
Results of cotransfection and luciferase assays showed 
that ZHX2 overexpression significantly decreased MDR1 
promoter activity in HepG2 and HepG2.2.15 cells (Figure 
6A). Conversely, ZHX2 knock-down by siRNAs greatly 
enhanced the MDR1 promoter activity in SMMC7721 
cells (Figure 6B). The decrease and increase in luciferase 
levels showed a dose-dependent response in cells that 
were cotransfected with ZHX2 expression vectors or 
ZHX2 siRNAs, respectively (Figure 6A and B). 
 Previous studies identified a NF-YA binding 
ATTGG element (known as Y box) in the MDR1 promoter 
that is important for full MDR1 promoter activity [9]. 
Furthermore, ZHX2 was shown to interact with the NF-
YA subunit and inhibit the ability of NF-Y to transactivate 
target genes [9]. To examine whether ZHX2 regulates 
MDR1 promoter activity via the Y box in HepG2 cells, 
ZHX2 cotransfections were performed with wild-type 
promoter pGL3-Mp or the pGL3-mMp in which the 
ATTGG motif was mutated (Figure 6C). In contrast to 
pGL3-Mp, the mutant promoter pGL3-mMp was not 
repressed by ZHX2 (Figure 6D). Furthermore, ZHX2-
mediated repression of the MDR1 promoter was dependent 
on NF-Y since this repression was no longer evident when 
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Figure 4: Increased ZHX2 levels in HepG2 cells enhance CDDP-induced apoptosis and activate the caspase pathway. 
HepG2 cells transfected with pcDNA3.0 or pcZHX2 were treated with CDDP for 24 hours. (A) Cells were incubated with PI and analyzed 
by flow cytometry. The percentage of cells with fragmented DNA (sub-G1 peak) are shown. (B) Staining of cells with Hoechst 33258 (upper 
images) and DAPI (lower images). Bars, 50 pixel . (C) Flow cytometry after staining with PI and Annexin V to determine the percentage of 
Annexin V-stained cells. (D) Western blot analysis to determine levels of ZHX2, Cytochrome C, full-length and cleaved caspase 3, cleaved 
caspase 9, full-length and cleaved PARP, and β-actin. Western blot data from three independent experiments are quantitated in the right 
panel, with levels if indicated protein shown relative to β-actin. *p < 0.05,**p < 0.01, ***p < 0.001.
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NF-YA was knocked down by siRNA (Figure 6E). 
 The transfection data described above led us to 
consider whether ZHX2 bound directly to the MDR1 
promoter or inhibited NF-Y activity by an indirect 
mechanism. As previous report in HEK-293, Co-IP 
demonstrated the interaction of ZHX2 and NF-YA 
proteins in HepG2 cells (Figure 7A) [9]. To directly test 
whether ZHX2 bound to the MDR1 promoter, ChIP were 
performed using HepG2 cells transfected with pcZHX2-
HA or pcEGFP-HA and oligonucleotides specific for the 
MDR1 promoter (Figure 6C). As shown in Figure 7B, a 
specific PCR amplification was detected in the anti-HA 
immunoprecipitation from HepG2 cells transfected with 
pcZHX2-HA but not in pcEGFP-HA, indicating that 
ZHX2 bound to the MDR1 promoter. Interestingly, a 
relative weak PCR amplification was detected in the anti-
NF-YA immunoprecipitation from HepG2 cells transfected 
with pcZHX2-HA than that in pcEGFP-HA (Figure 7 
B and C), suggested that the presence of transfected 
ZHX2 could influence the NF-YA binding to the MDR1 
promoter. Taken together, these data suggest that ZHX2 
interacts directly with NF-Y on the MDR1 promoter and 
that this interaction inhibits NF-Y-mediated activation of 
MDR1 transcription.
Figure 5: ZHX2 combined with CDDP act cooperatively to inhibit xenograft tumor growth in nude mice. Nude mice 
containing subcutaneous HepG2.2.15 tumors were randomized to receive intra-tumor injections of pcDNA3.0 or pcZHX2, and half of each 
group were also injected with CDDP. (A) Tumor volume was calculated every other day for the entire 16-day study. Data are shown as the 
mean±SD ( Two-way ANOVA, ***p < 0.001) . (B) Tumor weights in four different cohorts were measured at the end of the experiment. 
Data are shown as the mean±SD(n≥4); *p <0.05, **p<0.01. (C) Immunohistochemical analysis of ZHX2 expression in tumor samples. 
Bars, 20 pixel . (D) TUNEL staining as a measure of apoptosis in tumor samples indicate greatest staining in pcZHX2 plus CDDP injected 
tumors. Bars, 50 μm.
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Figure 6: ZHX2 represses MDR1 promoter activity via NF-YA-dependent interactions. (A) HepG2 and HepG2.2.15 cells 
were co-transfected with pGL3-Mp along with pcDNA3.0 or pcZHX2 (left panel) or with pGL3-Mp and increasing amounts of pcZHX2 
(right panel). (B) SMMC7721 cells were transfected with pGL3-Mp and siCON or ZHX2 siRNAs (left panel) or with pGL3-Mp and 
increasing amounts of ZHX2 siRNAs (right panel).(C) Diagram of the wild type and mutant type MDR1 promoters, showing the location 
of the Y box and the mutation used to generate pGL3-mMp. (D) HepG2 cells were co-transfected with pGL3-Mp or pGL3-mMp along with 
pcDNA3.0 or pcZHX2.(E) HepG2 cells were co-transfected with pGL3-Mp and pcDNA3.0 or pcZHX2(Left).In addition, cells were also 
transfected with siCON or NF-YA siRNA (siNF-YA ,Right). Data are shown as the mean ± SD (n≥3); *p < 0.05, **p < 0.01,***p < 0.001. 
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DISCUSSION
It is well established that MDR1/Pgp is a drug 
efflux pump responsible for the transport of a variety of 
antineoplastic drugs from the cells. Elevated MDR1 is 
strongly implicated in MDR and decreases the efficacy 
of cancer chemotherapy [3, 21]. Inhibition of MDR1/Pgp 
has been proposed as a powerful way to overcome efflux-
mediated chemotherapy resistance in cancer cells [3, 4]. 
Here, we identified the ubiquitous transcription factor 
ZHX2 as a negative regulator of MDR1 transcription. 
Increased ZHX2 levels led to reduced drug efflux and 
enhanced the cytotoxicity of anti-cancer drugs in HCC 
cell lines. Elevated ZHX2 levels significantly enhanced 
CDDP mediated suppression of liver tumor growth in vivo. 
These data are consistent with previous clinical studies 
demonstrating an association between ZHX2 expression 
and enhanced survival of patients with multiple myeloma 
Figure 7: ZHX2 interacts with the MDR1 promoter via NF-Y. (A) Co-IP of NF-YA and ZHX2 after transfection. pcZHX2 
plasmid was transfected into HepG2 cells, followed by immunoprecipitations performed as the methods. (B and C) ChIP analysis of 
DNA from HepG2 cells transfected with pcEGFP-HA or pcZHX2-HA . (B) Conventional PCR amplification of DNA was performed with 
primers specific to the MDR1 promoter after immunoprecipitation with anti-HA, anti-NF-YA or IgG (control). (C) DNA enrichment was 
analyzed at the MDR1 promoter by real-time PCR and the results are presented as fold of enrichment over input. Data are shown as the 
mean ± SD (n=3); ***p < 0.001.
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after chemotherapy treatment [17, 22]. 
ZHX2 was originally identified based on its 
interactions with ZHX1 and NF-Y [9]. Subsequently, 
ZHX2 was found to repress the expression of genes that 
are frequently upregulated in HCC, including AFP, GPC3 
and H19 [11, 12]. We recently identified cyclin A and 
cyclin E as ZHX2 targets [16]. Here, we added MDR1 as 
a new target of ZHX2. Based on our results, we propose 
that ZHX2 represses MDR1 transcription by interacting 
with NF-YA that is bound to the CCAAT box in the MDR1 
core promoter region. Previous studies demonstrated that 
NF-Y was an important regulator of MDR1 expression 
[6]. Our transient transfections confirmed the importance 
of the CCAAT box (Figure 6D) and the requirement of 
NF-Y (Figure 6E) for ZHX2-mediated repression. The 
co-immunoprecipitation assays confirmed previous 
reports showing interactions between ZHX2 and NF-YA 
(Figure 7A) [9]. This interaction between ZHX2 and NF-
YA on the MDR1 promoter was further verified by ChIP 
analysis (Figure 7 B and C). Previous studies identified 
NF-Y as a major component of MDR1 transcriptional 
complex, termed the MDR1 “enhancesome”, which is 
responsible for regulation of MDR1 transcription by a 
variety of stimuli, such as UV irradiation, HDAC (histone 
deacetylases) inhibitors and certain chemotherapeutics 
[23-25]. Moreover, NF-Y is required for recruitment 
of the histone acetyltransferase P/CAF or histone 
methyltransferase specific for H3K4 MLL1(mixed lineage 
leukemia 1) to the MDR1 promoter, resulting in the 
transcriptional activation that is likely mediated by further 
chromatin remodeling [24, 26]. Whether ZHX2 disturb 
the binding of the enhancesome and the recruitment of 
chromatin-modifying factors to the MDR1 promoter will 
require further studies. 
 Our data presented here demonstrate that 
ZHX2 inhibits MDR1 expression, which promotes the 
intracellular accumulation of chemotherapeutic drugs and 
increases their cytotoxic effects in HCC. This model is 
supported by ADM accumulation in HepG2 cell (Figure 
2C). The combined effect of ZHX2 and CDDP in the 
inhibition of tumor growth in vivo further supports the 
hypothesis. CDDP is generally believed to kill cancer 
cells by binding to DNA and interfering with cellular DNA 
repair mechanism, which eventually cause apoptosis [27, 
28]. As expected, we detected CDDP induced apoptosis in 
cultured HCC cells and HepG2.2.15 cells grown in nude 
mice. Although ZHX2 transfer alone did not cause obvious 
apoptosis, ZHX2 overexpression significantly increased 
CDDP-induced cell apoptosis both in vitro and in vivo 
(Figure 4 and 5D). In addition, western blots showed that 
combination of ZHX2 overexpression and CDDP led to 
increased release of cytochrome c and enhanced cleavaged 
caspase-3, caspase-9 and PARP (Figure 4D). This is 
consistent with the previous report which demonstrated 
the CDDP induced mitochondria-driven apoptosis in 
tumor cells [29]. Although chemotherapeutic agents exert 
their effects on tumor cells through various mechanisms, 
apoptosis is likely the final pathway shared by most 
chemotherapeutic agents [30, 31]. Nagel et al. found that 
ZHX2 activated STAT1 signaling, which could contribute 
to apoptosis [15]. This raises the potential that ZHX2 
promotes chemotherapy effects by regulating apoptosis 
related genes and might lead to efflux-independent 
chemotherapy resistance in HCC cells. 
 We recently reported that ZHX2 inhibits Cyclin 
A and Cyclin E expression, leading to HCC cell cycle 
arrest [16]. This indicates that ZHX2 functions as a tumor 
suppressor in HCC. Our data provided here indicates that 
ZHX2 represses MDR1 expression and therefore enhances 
the effect of chemotherapy via increased intracellular 
drug concentration. This is therefore a second mechanism 
by which ZHX2 influence HCC cell growth. Further 
investigation using clinical specimens will be required 
to determine whether abnormal ZHX2 expression in 
liver tumors may be used as a potential biomarker for 
predicting chemotherapeutic drug resistance. Our data 
also suggest that increasing ZHX2 levels may decrease 
the growth of HCC cells and increase their sensitivity to 
chemotherapeutic agents. Identifying additional ZHX2 
targets may also elucidate other HCC therapy targets. In 
conclusion, the results provide a basis for further clinical 
research in combining ZHX2 and chemotherapeutic agents 
to treat liver cancer.
MATERIALS AND METHODS
Cell lines, plasmids and siRNAs
The human HCC cell lines SMMC7721 were 
cultured in RPMI 1640. Human hepatoma cell lines 
HepG2 were cultured in minimum essential medium 
(MEM) with 1mmol/L sodium pyruvate. HepG2.2.15 
cells were cultured in MEM with 380 μg/ml G418 
(GIBCO). Human embryonic kidney 293 (HEK293) cells 
were cultured in Dulbecco’s modified Eagle’s medium. 
All the cells were purchased from Shanghai Institute of 
Cell Biology (Chinese Academy of Sciences ,Shanghai, 
China), and all the media were supplemented with 10% 
fetal bovine serum (FBS, GIBCO).
 ZHX2 expression vectors pcZHX2 and pEGFP-
ZHX2 and the siRNAs against ZHX2 (ZHX2-1674, 
ZHX2-2360) were described previously [16]. pcEGFP-
HA was constructed by cloning the EGFP-HA to the 
pcDNA3.0 plasmid. The promoter regions of human 
MDR1(-137 to +158, the transcription initiation site 
designated as +1) was cloned into the promoterless pGL3-
basic vector (Promega) to prepare luciferase reporter 
plasmid (pGL3-Mp). Reporter plasmid containing mutant 
MDR1 promoter (pGL3-mMp) was constructed by 
mutating the wild-type Y-box (ATTGG to ACTCG). The 
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siRNA against NF-YA was purchased (sc-2997, Santa 
Cruz, CA, USA). 
RT-PCR and Western blot
Total RNA extracted with TRIzol reagent 
(Invitrogen) were reverse transcribed into cDNAs using a 
Thermo Scientific RevertAid First Strand cDNA Synthesis 
Kit. Conventional PCR was carried out in a BioRad 
Thermal Cycler with specific primers (Table S1).
 Cytoplasmic extracts and whole cell extracts 
were prepared as described previously [16]. 40 µg 
of protein separated by SDS-PAGE were bloted with 
following antibodies: anti-ZHX2 (ab56886, Abcam, 
MA, USA), anti-β-actin (sc-1616-R, Santa Cruz, CA, 
USA), anti-MDR1(sc-55510, Santa Cruz, CA, USA) and 
anti-cytochrome c (4280), anti-caspase-3 (9668), anti-
caspase-9 (9508), anti-PARP (9532) from Cell Signal 
Technology, MA, USA. 
Cytotoxicity assay
To evaluate the effect of ZHX2 on the toxicity of 
chemotherapeutic drugs, ZHX2-overexpressing cells 
or ZHX2-knockdown cells were treated with Cisplatin 
(CDDP, 20μg /ml; QiLu Pharmaceutical, Jinan, China) or 
Adriamycin (ADM, 20 μg/ml; Pfizer Pharm, NY, USA) 
for 24 hours. Cell viability was assayed using the Cell 
Counting Kit-8 (CCK-8, Dojindo, Shanghai, China). The 
cytotoxicity index was calculated as (1 - OD450 of drug-
treated cells / OD450 of untreated cells) × 100%. The 
IC50 values of CDDP and ADM were calculated using 
GraphPad Prism 5 (Version 5.01, GraphPad Software, San 
Diego, CA) [32]. 
Cell cycle and apoptosis analysis
Cells transfected with pcZHX2 or pcDNA3.0 were 
treated with CDDP (20µg/ml) for 24 hours. Apoptotic 
cells were estimated either by Hoechst 33258 (1 µg/ml, 
Promega) or DAPI (1 µg/ml, Promega) staining or flow 
cytometry with the Apoptosis detection kit (BU-AP0103, 
Biouniquer Technology Co, Ltd, Nanjing, China). The cell 
cycle were anlayzed by flow cytometry after propidium 
iodide (PI, Sigma, USA) staining. Flow cytometery 
were performed with Beckman Coulter Flow Cytometer 
(Miami, USA). 
Clinical samples and immunohistochemical 
staining
To estimate the correlationship of ZHX2 and MDR1 
in HCC, ZHX2 and MDR1 immunohistochemical staining 
was performed in HCC tissues from 30 HCC patients 
(Table S2) who underwent surgery between 30 October 
2013 and 29 August 2014 at Qilu Hospital and Shandong 
Provincial Hospital affiliated to Shandong University 
(Shandong, China). None of the patients was positive for 
HCV or HIV. Informed consent was obtained from all 
patients before the study was initiated with approval of 
the Shandong University Medical Ethics Committee in 
accordance with the Declaration of Helsinki. 
Immunohistochemical staining using anti-ZHX2 
(ab56886, Abcam, MA, USA) and anti-MDR1 (sc-
55510, Santa Cruz, CA, USA) antibody was performed 
and analyzed as described previously [16]. Eight fields 
of ~1000 cells from each HCC sections were counted 
independently by three pathologists. Nuclear ZHX2 
staining and membrane MDR1 staining were reported 
separately according to the German semi-quantitative 
scoring system [33, 34]. Briefly, each sample was scored 
according to staining intensity (no staining = 0; weak 
staining = 1; moderate staining = 2; strong staining 
= 3) and the number of stained cells (0% = 0; 1-25% 
= 1; 26-50% = 2; 51-75% = 3; 76-100% = 4). Final 
immunoreactive scores were determined by multiplying 
the staining intensity by the number of stained cells, with 
minimum and maximum scores of 0 and 12, respectively 
[35].
In vivo xenograft tumor studies 
Male Balb/c nude mice (4~6 weeks of age) were 
purchased from the Animal Research Committee of 
Institute of Biology and Cell Biology (Shanghai, China) 
and housed under specific pathogen-free conditions 
according to protocols approved by the Shandong 
University Animal Care Committee. In vivo studies 
were performed as described previously [16]. Briefly, 
HepG2.2.15 cells xenografts were prepared and treated by 
intratumoral injection of pcZHX2 (20 µg) or pcDNA3.0 
(20 µg) together with CDDP (80 µg) at 3 days interval 
for four times. The tumor volume and tumor weight were 
estimated. Animal experiments(6 mice per group) were 
repeated at least twice. 
TUNEL assays
Detection of apoptosis in mouse tumor tissues was 
carried out by terminal deoxyribonucleotidyl transferase-
mediated dUTP nicked labeling (TUNEL) analysis ,and 
was performed according to the manufacturer’s protocol 
(In Situ Cell Death Detection Kit , Fluorescein Roche, Cat.
No.11684795910 ). 
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Intracelluar drug accumulation and retention 
assay
The natural red fluorescence of the chemotherapeutic 
drug ADM was used to determine drug accumulation 
and retention[36]. Briefly, HepG2 cells transfected with 
pEGFP-ZHX2 were cultured in medium with 40µg/
ml ADM for 4 hours at 37oC. Drug accumulation in the 
cells was estimated either by fluorescence microscope or 
flow cytometry. For flow cytometry, cells were gated as 
EGFP-positive and EGFP-negative, then red MFI of the 
gated cells was used to determine drug accumulation. 
To measure the drug retention, ADM treated cells were 
cultured with fresh, drug-free medium for another 2 hours 
allowing drug efflux from cells. The ADM releasing index 
of HepG2 cells was calculated as following: releasing 
index = (accumulation MFI-retention MFI)/accumulation 
MFI. 
Co-immunoprecipitation(Co-IP)
Cell lysates from HepG2 cells transfected with 
pcZHX2 were precipitated with control IgG (sc-2027, 
Santa Cruz, CA, USA) or NF-YA antibody (ab6558; 
Abcam, Hong Kong). After incubation with protein 
A/G Plus-Agarose(sc-2003, Santa Cruz, CA, USA), the 
precipitates were immunobloted with anti-HA antibody 
(ab9110; Abcam).
Chromatin immunoprecipitation(ChIP) assays
ChIP assays was performed with HepG2 cells 
transfected with pcZHX2-HA or pcEGFP-HA as reported 
[16]. Briefly, fixed cells were sonicated to shear DNA 
to 200~1000 bp and immunoprecipitated using anti-HA 
antibody (ab9110; Abcam), anti-NF-YA antibody (ab6558; 
Abcam) or rabbit IgG (sc-2027, Santa Cruz, CA, USA). 
As controls, 1/20th of the starting chromatin (Input) was 
used. Analysis was performed using specific primers for 
the NF-YA binding region of MDR1 promoter.
Real-time quantitative PCR
Real-time quantitative PCR was carried out in 
BioRad C1000TM Thermal Cycler CFX96TM Real-
Time System using SuperReal PreMix Plus (SYBR 
Green,TIANGEN BIOTECH,BEIJING). The results are 
presented as fold of enrichment over input. The used 
primers were shown in Table S1.
Luciferase reporter assays
HCC cell lines were transfected with reporter 
plasmids (0.2µg) and pcZHX2(0.4µg) or ZHX2 siRNAs 
using LipofectamineTM 2000(Invitrogen). To further 
explore the role of NF-YA in ZHX2 mediated control of 
the MDR1 promoter, HepG2 cells were co-transfected with 
reporter plasmids, NF-YA siRNA and pcZHX2. Luciferase 
reporter assay was performed using Dual-Luciferase 
Reporter Assay System (Promega). 
Statistics
GraphPad Prism (GraphPad Software, San Diego, 
CA) was used for data analysis. Data values were 
presented as the means ± SD. The statistical correlation 
between the MDR1 staining levels and the ZHX2 staining 
levels in tissue sections was analyzed by the Chi-square 
test. Two-way ANOVA followed by Bonferroni post-
tests was applied to determine significant differences 
between different treatments in xenograft tumor studies. 
The Student t-test was applied to determine significant 
differences between groups. In these analyses, p <0.05 
were considered to statistically significant.
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